1. Alas S, Bonavida B . (2001). Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 61: 5137–5144.
2. Alas S, Bonavida B . (2003). Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res 9: 316–326.
3. Alas S, Emmanouilides C, Bonavida B . (2001). Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clinc Cancer Res 7: 709–723.
4. Baritaki S, Huerta-Yepez S, Sakai T, Spandidos S, Bonvida B . (2007). Mol Cancer Ther (in press).
5. Bezombes C, Grazide S, Garret C, Fabre C, Quillet-Mary A, Muller S et al. (2004). Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood 104: 1166–1173.